| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000468 | BKPyv | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30001116 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30016067 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30004832 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30014260 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30008161 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30017257 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30016998 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30019395 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30019405 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | IL2RB |
|---|---|
| DrugBank ID | DB00111 |
| Drug Name | Daclizumab |
| Target ID | BE0000651 |
| UniProt ID | P14784 |
| Regulation Type | antibody |
| PubMed IDs | 12372041; 15022409; 15814281; 2571203; 2647626; 11752352 |
| Citations | Light JA, Sasaki TM, Ghasemian R, Barhyte DY, Fowlkes DL: Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. Clin Transplant. 2002;16 Suppl 7:30-3.@@Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]. Rev Med Chil. 2003 Dec;131(12):1445-53.@@Forrest K, Logan B, Strange J, Roszman TL, Goebel J: Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo? Transpl Immunol. 2005 Mar;14(1):43-7. Epub 2005 Jan 4.@@Ramos EL, Milford EL, Kirkman RL, Tilney NL, Strom TB, Shapiro ME, Waldmann TA, Wood IG, Rollins MR, Carpenter CB: Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. Transplantation. 1989 Sep;48(3):415-20.@@Burkhardt K, Mandel TE, Diamantstein T, Loughnan MS: Anti-IL-2 receptor monoclonal antibody AMT-13 increases soluble IL-2 receptor levels in vivo. Immunology. 1989 Feb;66(2):183-9.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Investigational; Withdrawn |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA164764446 |
| ChEMBL | CHEMBL1201605 |
